MedCognetics receives FDA 510(k) clearance for CogNet AI-MT+, an AI tool for breast imaging triage. Enhances early cancer detection with unbiased algorithms trainedMedCognetics receives FDA 510(k) clearance for CogNet AI-MT+, an AI tool for breast imaging triage. Enhances early cancer detection with unbiased algorithms trained

FDA Clears MedCognetics’ Enhanced AI Software for Prioritizing Suspicious Mammograms

2026/02/06 00:30
Okuma süresi: 2 dk

The U.S. Food and Drug Administration has granted 510(k) clearance to MedCognetics for its CogNet AI-MT+ radiological computer-aided triage and notification software. This regulatory milestone permits the commercialization of the enhanced AI-enabled device in the United States under 21 CFR 892.2080, with the FDA determining it to be substantially equivalent to legally marketed predicate devices.

CogNet AI-MT+ is designed to integrate into existing imaging systems to help radiologists manage increasing imaging volumes by flagging suspicious 3D mammography exams for prioritized review. The software employs advanced artificial intelligence and machine learning to detect early signs of cancer across all ethnicities, reflecting MedCognetics’ mission to improve health equity through unbiased AI. The platform is trained on a diverse global dataset specifically to mitigate data bias, which the company believes represents the future of AI in healthcare.

This clearance expands MedCognetics’ regulatory footprint in AI-driven breast imaging. The CogNet AI-MT+ device is part of the company’s comprehensive CogNet AI platform, which is designed to enhance radiologists’ capabilities by expanding insights and awareness in medical imaging. The platform aims to advance the performance of radiologists and imaging centers while delivering accurate care for patients worldwide.

MedCognetics provides an advanced AI software platform that integrates into radiology workflow, with the company based in Dallas, Texas. For more information about their technology and approach, visit their website at https://www.medcognetics.com. The FDA clearance represents a significant step in implementing AI solutions that can help address workflow challenges in radiology departments while maintaining a focus on equitable healthcare outcomes through technology designed to perform consistently across diverse patient populations.

Blockchain Registration, Verification & Enhancement provided by NewsRamp™

This news story relied on content distributed by Reportable. Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is FDA Clears MedCognetics’ Enhanced AI Software for Prioritizing Suspicious Mammograms.

The post FDA Clears MedCognetics’ Enhanced AI Software for Prioritizing Suspicious Mammograms appeared first on citybuzz.

Sorumluluk Reddi: Bu sitede yeniden yayınlanan makaleler, halka açık platformlardan alınmıştır ve yalnızca bilgilendirme amaçlıdır. MEXC'nin görüşlerini yansıtmayabilir. Tüm hakları telif sahiplerine aittir. Herhangi bir içeriğin üçüncü taraf haklarını ihlal ettiğini düşünüyorsanız, kaldırılması için lütfen service@support.mexc.com ile iletişime geçin. MEXC, içeriğin doğruluğu, eksiksizliği veya güncelliği konusunda hiçbir garanti vermez ve sağlanan bilgilere dayalı olarak alınan herhangi bir eylemden sorumlu değildir. İçerik, finansal, yasal veya diğer profesyonel tavsiye niteliğinde değildir ve MEXC tarafından bir tavsiye veya onay olarak değerlendirilmemelidir.